We would love to hear your thoughts about our site and services, please take our survey here.
Keeping my eye on the Ball and not listening to the BULL.... Or should i Say the Bear.... ?
Everyone to their own :-)
Pokerchips,
I agree With you about contracts being ammendable but Imm would need to inform the market on any changes to the contract...
So as things stand , one should ASSUME that if the costs go over that initial figure, it would be upto IMM to pay the difference,imo
Pokerchips,
The up to figure of $25 million IS what IS written on the contract and should therefore be taken for what it IS and not what you would like it to be ( i.e. flexible)
Imo
What could be important however IS the Tax credit/ research credits... These will depend on where/how/WHO, but there are a few millions AT stake so let's see what Avion and IMM have negociated regarding those millions :-)
Pokerchips,
Most People fail to understand that Lupuzor 1 IS No longer and therefore a major U turn has been made and they had to go Back to the starting blocks With the New Lupuzor i.e formulation testing/ patent protection etc etc
Whilst lessons have surely been learnt , they still have a long Road to go ..
Many Time related effects have to be analysed and reported to the advisors to optimise the protocol for the future P2 part of the trial so it's all to work on ..
All in my opinion of course ...
Wildbunch,
Very difficult question to answer as we haven't yet seen the protocol and how many patients have to be recruited
Let's wait and see when the study IS published on the clinical trials website , we should know a bit more then...
Not really surprised by the lack of apparent progress as clinical trial setup IS a very technical and burocratic process.
One has to tick off many boxes before giving the green light because of Tax / subsidies issues etc etc ... There are millions of pounds at stake so one has to get it fine tuned , imo
But everyone to their own as usual
Dallo,
It may bé friday and you may bé feeling good but your prédictions in the have been basically wrong and once more i think you are wrong again ..
If Alora had any intention of doing a bid for IMM , they would have participated in the last two share placings AT 5p and AT 2p imho ( instead of getting their stake massively diluted ) .
I don't also believe that the ' French Connection' would give the green might to any Alora takeover ...
In the meantime i would really like to see Alora spending some major monies in the P2-P3 trial ..
Trek,
On top of the purchase Price , hospitals have to include recyclage/disposant costs .
Also , in the last few years there has been a shortage of gadolinium, leaving some hospitals unable to undertake/ postpone some MRI's
Keeping my investment here in the bottom drawer and awaiting FDA news
Exactly
EVGEN issued the RNS this morning
Should'nt make much difference but whatever
Existing shareholders , especially those that have been holding for many years are thé ones that are the most affected by dilution as their averages are well above achievable levels EVEN with major news , Imo
For those newbies who might invest now, At thèse levels , won't really Care as they will bé speculating on good news to Come and no further dilution to anticipate in the meantime ( excepting the warrants which have already been annonced )
Promises are one thing but results are another so only Time will tell !
Wildbunch,
Some peuple were mentioning the enormous dilution to Come for a while but were dismissed for talking nonsense.
This New placing which was inevitable just goes to show the scale of what dilution Can Do ..
Imm needs to fund their pipeline with partnership deals and not from placings but that may happen in the future so keep the faith !